$280.490
-3.983 (-1.42%)收盘时
LGND 资讯
LGND 事件
Agenus Enters $85M Securities Purchase Agreement
Agenus (AGEN) announced that it has entered into a securities purchase agreement for a private placement of approximately $85M in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255M upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals (LGND). The private placement is expected to close on or about July 15.
Ligand Pharmaceuticals Announces $625 Million Convertible Notes Pricing
Ligand Pharmaceuticals announced the pricing of $625.0 million aggregate principal amount of 0.0% convertible senior notes due 2031 in a private placement to persons reasonably believed to be qualified institutional buyers. Upon conversion, Ligand will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, shares of Ligand's common stock or a combination of cash and shares of Ligand's common stock, at Ligand's election, in respect of the remainder, if any, of Ligand's conversion obligation in excess of the aggregate principal amount of the notes being converted. The conversion rate will initially be 2.9916 shares of Ligand's common stock per $1,000 principal amount of notes (equivalent to an initial conversion price of approximately $334.27 per share of Ligand's common stock). The initial conversion price of the notes represents a premium of approximately 27.5% over the last reported sale price of Ligand's common stock on the Nasdaq Global Market on June 22, 2026.
Ligand Pharmaceuticals to Offer $550M Convertible Senior Notes in Private Placement
Ligand Pharmaceuticals announced its intention to offer $550M aggregate principal amount of convertible senior notes due 2031 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Ligand Reaffirms FY26 Revenue Guidance of $270M-$310M
Backs FY26 revenue view $270M-$310M, consensus $288.97M. The company said, "Ligand is reaffirming its 2026 full-year financial guidance, which was raised on April 27, 2026 in connection with the announced entry into a definitive agreement to acquire XOMA. The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including approval by XOMA stockholders, and certain entity restructuring."
Ligand Q1 Revenue $51.72M, Below Consensus
Reports Q1 revenue $51.72M, consensus $58.86M. "The first few months of 2026 have already proven to be highly productive and transformative for Ligand," said Todd Davis, CEO of Ligand. "In April, we announced a definitive agreement to acquire XOMA Royalty Corporation, a highly complementary business that we expect to accelerate both near and long-term growth. Upon closing, the transaction will add more than 120 commercial, clinical and preclinical-stage assets to our royalty portfolio, including seven commercial assets and 14 late-stage programs, and meaningfully diversify Ligand across therapeutic areas, stages of development, and biopharma partners. We were also pleased to see the full FDA approval of Filspari in focal segmental glomerulosclerosis ("FSGS"), a transformative milestone that further strengthens one of our most valuable royalty assets. Filspari is now the largest royalty contributor within our commercial portfolio and, as the first and only FDA-approved medicine for this rare and serious kidney disease, is well positioned to be a key driver of long-term royalty growth."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。